Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx reports encouraging results from Phase II ulcer trial
RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tâ4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with
RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tâ4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with
Under the terms of the proposal, each share of Exact Sciences would be exchanged for $1.50 in Sequenom common stock. This consideration would be subject to a floating
This program involves two clinical trials, taking place in the US (TG MV-006 trial) and Europe and North America (TG-MV-007 trial). The start of these pivotal clinical trials
UCB retains exclusive rights to re-purchase each of the five programs, following completion of initial clinical feasibility studies for each program, and assume the responsibility for further development
The company has also filed several patents associated with the development of peptides and proteins derived from ‘state-dependent’ physiologies to advance the treatment of a variety of human
The safety and efficacy of AllerNaze nasal spray in both seasonal allergic rhinitis and perennial allergic rhinitis have been well established in 14 controlled clinical trials involving almost
Delayed graft function (DGF) represents Quark’s second indication being evaluated for the systemically administered drug candidate in human clinical trials. This trial follows two currently enrolling Phase I
Under the terms of the agreement EuroCept will pay Stellar an upfront milestone payment, plus an ongoing royalty on in-market sales and specified transfer price in exchange for
The Phase II trial is a double-blinded, randomized, dose-ranging, placebo-controlled study designed to assess cobiprostone’s efficacy and safety for preventing non-steroidal anti-inflammatory drugs-induced ulcers in patients with arthritis.
This commitment is part of Tekmira’s manufacturing relationship with Alnylam through Phase II clinical development for RNAi therapeutics that utilize Tekmira’s stable nucleic acid-lipid particles (SNALP) technology, including